AAV Vector miRNA Delivery for SBMA Androgen Receptor Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Spinal and Bulbar Muscular Atrophy (SBMA) are ineffective, and there is a need for a therapeutic approach that can safely reduce the levels of the androgen receptor protein in motor neurons to mitigate the disease progression.
Innovation Solution
A recombinant, replication-defective adeno-associated virus (AAV) is developed, carrying a vector genome that expresses a microRNA (miRNA) specifically targeting the androgen receptor in motor neurons, using an AAVhu68 capsid with a vector genome comprising an expression cassette including a CMV enhancer, CBA promoter, chimeric intron, woodchuck post-regulatory element, and poly A sequences to inhibit androgen receptor expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen receptor levels are reduced in motor neurons to treat SBMA, then disease progression is mitigated and motor function is improved, but the therapeutic approach must ensure specific targeting to avoid off-site effects
Solution Approach 1:
The patent employs tissue-specific promoters (such as MBP promoter for motor neurons, or CaMKIIα promoter for spinal cord) to ensure that the androgen receptor knockdown therapy is expressed only in the target tissue. This localizes the therapeutic effect to motor neurons while preventing off-site effects in other tissues, directly resolving the contradiction between therapeutic efficacy and harmful off-site effects.
Solution Approach 2:
The patent uses viral vectors (such as AAV2, AAV5, or AAVrh10) as intermediaries to deliver the therapeutic nucleic acid sequence specifically to motor neurons. These vectors act as mediators that can cross the blood-brain barrier and target specific cell types, enabling precise delivery of the androgen receptor knockdown therapy without causing widespread off-site effects.
2Productivity
If viral vectors are used to deliver miRNA targeting androgen receptor, then therapeutic delivery is achieved, but vector genome integration and replication control must be managed
Solution Approach 1:
The patent extracts and removes the replication genes (rep and cap) from the viral vector genome, creating a replication-defective vector. This extraction eliminates the risk of viral replication and genome integration while maintaining the ability to deliver the therapeutic miRNA sequence, thus resolving the contradiction between delivery efficiency and genome stability.
Solution Approach 2:
The patent employs a non-integrating viral vector system that does not require permanent genome integration to achieve therapeutic effect. The vector delivers the miRNA sequence transiently without integrating into host DNA, avoiding long-term genomic instability. This approach treats the vector as a temporary delivery mechanism rather than a permanent modification, resolving the reliability concern regarding vector genome integration.
3Duration of action of moving object
If miRNA is expressed to knock down androgen receptor, then disease progression is slowed, but expression control and regulatory sequences must be precisely managed
Solution Approach 1:
The patent divides the expression cassette into distinct functional segments: tissue-specific promoter, miRNA coding sequence, and regulatory elements (such as WPRE and polyA signal). This segmentation allows each component to be independently optimized for its specific function while simplifying the overall design and assembly process, resolving the contradiction between duration of action and cassette complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV-mediated delivery of miRNA effectively knocks down the androgen receptor in both preclinical models and non-human primates, showing promise in slowing down disease progression and improving motor function and survival in SBMA patients.
Implementation Method 1
The miRNA inhibits expression of human androgen receptor. The vector genome includes an expression cassette comprising a nucleic acid sequence encoding at least one hairpin forming miRNA that comprises a targeting sequence that binds a miRNA target site on the mRNA of human androgen receptor.
Data Source
AI summary
Compositions useful for treatment of Spinal and Bulbar Muscular Atrophy (SBMA) comprising administration of a recombinant adeno-associated virus (rAAV) vector having an AAV capsid and a vector genome comprising a sequence encoding at least one hairpin forming miRNA that comprises a targeting sequence which binds a target site on the mRNA of human androgen receptor, wherein the miRNA inhibits expression of human androgen receptor, is provided. Also provided are compositions containing a rAAV vector and methods of treating SBMA in patient comprising administration of a rAAV vector.